GALT Straddle Strategy
GALT (Galectin Therapeutics Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
GALT (Galectin Therapeutics Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $146.8M, a beta of 0.45 versus the broader market, a 52-week range of 1.21-7.13, average daily share volume of 326K, a public-listing history dating back to 2002, approximately 15 full-time employees. These structural characteristics shape how GALT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.45 indicates GALT has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a straddle on GALT?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current GALT snapshot
As of May 15, 2026, spot at $2.23, ATM IV 177.80%, IV rank 45.88%, expected move 50.97%. The straddle on GALT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this straddle structure on GALT specifically: GALT IV at 177.80% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 50.97% (roughly $1.14 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated GALT expiries trade a higher absolute premium for lower per-day decay. Position sizing on GALT should anchor to the underlying notional of $2.23 per share and to the trader's directional view on GALT stock.
GALT straddle setup
The GALT straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With GALT near $2.23, the first option leg uses a $2.23 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed GALT chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 GALT shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $2.23 | N/A |
| Buy 1 | Put | $2.23 | N/A |
GALT straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
GALT straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on GALT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on GALT
Straddles on GALT are pure-volatility plays that profit from large moves in either direction; traders typically buy GALT straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
GALT thesis for this straddle
The market-implied 1-standard-deviation range for GALT extends from approximately $1.09 on the downside to $3.37 on the upside. A GALT long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current GALT IV rank near 45.88% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on GALT should anchor more to the directional view and the expected-move geometry. As a Healthcare name, GALT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to GALT-specific events.
GALT straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. GALT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move GALT alongside the broader basket even when GALT-specific fundamentals are unchanged. Always rebuild the position from current GALT chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on GALT?
- A straddle on GALT is the straddle strategy applied to GALT (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With GALT stock trading near $2.23, the strikes shown on this page are snapped to the nearest listed GALT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are GALT straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the GALT straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 177.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a GALT straddle?
- The breakeven for the GALT straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current GALT market-implied 1-standard-deviation expected move is approximately 50.97%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on GALT?
- Straddles on GALT are pure-volatility plays that profit from large moves in either direction; traders typically buy GALT straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current GALT implied volatility affect this straddle?
- GALT ATM IV is at 177.80% with IV rank near 45.88%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.